Trial · NCT07365410
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
NCT07365410, Phase 2, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study. Trials, record NCT07365410. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07365410
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
- NCT number
- NCT07365410
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
- Interventions
- Furmonertinib, Furmonertinib, carboplatin, pemetrexed
- First posted
- 2026-01-26
- Last updated
- 2026-01-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Progression-Free Survival (PFS) as assessed by Investigator | Approximately 18 months after the first patient begin study treatment | The time from the first dose of the study drug to the progression of the disease (Investigator-Assessed) or death for any reason according to investigator. |
| Secondary | Objective Response Rate (ORR) as assessed by RECIST 1.1 | Approximately 12 weeks following the first dose of study drug | Proportion of subjects whose tumors were assessed as complete response(CR) or partial response(PR) according to RECIST 1.1. |
| Secondary | Disease Control Rate (DCR) as assessed by RECIST 1.1 | Approximately 18 months from the first patient begin study treatment | Proportion of subjects whose tumors were assessed as CR, PR or stable disease (SD) according to RECIST 1.1. |
| Secondary | Central Nervous System (CNS) Objective Response Rate (CNS ORR) as assessed by RECIST 1.1 | Approximately 12 weeks after the first dose of study drug | Proportion of subjects whose central nervous system (CNS) tumors (including intracranial parenchymal metastases and asymptomatic meningeal metastases as defined in the inclusion criteria) are assessed as Complete Response (CR) or Partial Response (PR) according to RECIST1.1. |
| Secondary | Central Nervous System (CNS) Disease Control Rate (CNS DCR) as assessed by RECIST 1.1 | Approximately 18 months after the first dose of study drug | Proportion of subjects whose central nervous system (CNS) tumors (including intracranial parenchymal metastases and asymptomatic meningeal metastases as defined in the inclusion criteria) are assessed as Complete Response (CR), Partial Response (PR), or Stable Disease (SD) according to RECIST 1.1. |
| Secondary | Central Nervous System Progression-Free Survival (CNS PFS) as assessed by RECIST 1.1 | Approximately 18 months after the first dose of study drug | The time from the first dose of the study drug (Furmonertinib) to the first occurrence of central nervous system (CNS) disease progression (assessed by RECIST 1.1) or death from any cause, whichever comes first. |
| Secondary | Median Overall Survival (OS) | Approximately 24 months after the first dose of study drug | The time from the first does of the study drugs to the death for any reason |
| Secondary | Safety Profile (Adverse Events, AE) as assessed by CTCAE v5.0 | From the start of study drug to 28 days after the last dose of study drug | The number of patients with adverse events and the severity grading (Grade 1-5) according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
| Secondary | Progression Pattern as assessed by RECIST 1.1 and Clinical Evaluation | Approximately 18 months after the first dose of study drug | Proportion of subjects with first disease progression classified as Intracranial, extracranial, or combined intracranial-extracranial progression. |
| Secondary | Site Analysis of Disease Progression as assessed by RECIST 1.1 and Clinical Evaluation | Approximately 18 months after the first dose of study drug | Frequency of specific progression sites. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07365410
GET https://conductscience.org/api/trials/v1/NCT07365410/registered